Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14 USD | +3.70% | +3.70% | -17.55% |
05-28 | Transcript : Neuren Pharmaceuticals Limited - Shareholder/Analyst Call | |
05-27 | Neuren Phase 2 Trial Shows Significant Improvements in Pitt Hopkins Syndrome | CI |
Sales 2024 * | 152M 100M 7.87B | Sales 2025 * | 172M 113M 8.92B | Capitalization | 2.49B 1.64B 129B |
---|---|---|---|---|---|
Net income 2024 * | 91M 59.89M 4.71B | Net income 2025 * | 99M 65.16M 5.12B | EV / Sales 2024 * | 14.3 x |
Net cash position 2024 * | 318M 209M 16.45B | Net cash position 2025 * | 431M 283M 22.28B | EV / Sales 2025 * | 11.9 x |
P/E ratio 2024 * |
27.2
x | P/E ratio 2025 * |
25.3
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 83.53% |
Latest transcript on Neuren Pharmaceuticals Limited
1 day | +3.70% | ||
1 week | +3.70% | ||
1 month | +11.91% | ||
3 months | +14.57% | ||
6 months | +34.62% | ||
Current year | -17.55% |
Managers | Title | Age | Since |
---|---|---|---|
Jon Pilcher
CEO | Chief Executive Officer | 58 | 18/08/13 |
Lauren Frazer
DFI | Director of Finance/CFO | - | 31/07/20 |
Liza Squires
CTO | Chief Tech/Sci/R&D Officer | - | 07/07/22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 63 | 04/03/02 | |
Dianne Angus
BRD | Director/Board Member | 63 | 04/07/18 |
Jenny Lee Harry
BRD | Director/Board Member | - | 04/07/18 |
Date | Price | Change | Volume |
---|---|---|---|
31/05/24 | 14 | +3.70% | 5,023 |
Delayed Quote OTC Markets, May 31, 2024 at 08:04 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+45.82% | 754B | |
+40.95% | 630B | |
-6.16% | 352B | |
+19.86% | 331B | |
+9.32% | 298B | |
+18.45% | 250B | |
+11.88% | 217B | |
-0.78% | 216B | |
+5.90% | 164B |
- Stock Market
- Equities
- NEU Stock
- NURPF Stock